Reuters logo
BRIEF-Fountain Biopharma receives FDA Orphan Drug Designation for new drug FB825
October 11, 2017 / 3:26 AM / 6 days ago

BRIEF-Fountain Biopharma receives FDA Orphan Drug Designation for new drug FB825

Oct 11 (Reuters) - Fountain Biopharma Inc :

* Says it received FDA Orphan Drug Designation for Anti-CemX antiallergic monoclonal antibody new drug FB825, which is used for treatment of Hyper IgE Syndrome, from U.S Food and Drug Administration Source text in Chinese: goo.gl/cLWdA4 Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below